Preventive VT Substrate Ablation in Ischemic Heart Disease (PREVENT-VT)
Ventricular Tachycardia, Ventricular Arrythmia, Sudden Cardiac Death
About this trial
This is an interventional treatment trial for Ventricular Tachycardia focused on measuring ventricular tachycardia, ventricular arrhythmia, sudden cardiac death, ischemic heart disease, cardiac magnetic resonance, border zone channels
Eligibility Criteria
Inclusion Criteria:
- Age > 18 years.
- Chronic, stable ischemic heart disease, irrespectively of the LVEF.
- Life expectancy of > 1 year with a good functional status.
- Documented scar AND a BZC mass > 5.15 g as measured per LGE-CMR and automatic post-processing using the ADAS-3D LV (ADAS 3D Medical SL, Barcelona, Spain).
- Signed informed consent.
Exclusion Criteria:
- Age < 18 years.
- Pregnancy.
- Life expectancy of < 1 year, or bad functional status (NYHA IV functional class).
- Other concomitant structural heart diseases (e.g. congenital, non-ischemic, etc.)
- Previously documented sustained ventricular arrhythmias.
- Impossibility to perform a contrast-enhanced CMR study.
- Calculated BZC mass in the scarred tissue < 5.15 g using the ADAS-3D LV software.
- Concomitant investigation treatments.
- Medical, geographical and social factors that make study participation impractical, and inability to give written informed consent. Patient's refusal to participate in the study.
Sites / Locations
- Centro Medico TeknonRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
ABLATE arm
NO-TREAT arm
Ventricular tachycardia substrate ablation intending to: i) eliminate all the potential arrhythmogenic substrate, aiming for complete electrical isolation/elimination of all the electrograms with delayed components or showing hidden slow conduction properties, and ii) non-inducibility or ventricular tachycardias at the end of the procedure. Standard medical treatment will also be given for these patients.
Only standard medical treatment will be offered for these patients.